Viveve Medical is part of the healthcare sector and trades as part of the medical devices industry. The company CEO is Scott C. Durbin. Viveve Medical Inc is a women’s sexual health company focused on the commercialization of a non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue.
Previous Intraday Performance:
The VIVE shares had a previous change of 0.33% which opened at 0.47 and closed at 0.46. It moved to an intraday high of 0.48 and a low of 0.46.
Over the last five trading days, VIVE shares returned -5.82% and in the past 30 trading days it returned -9.51%. Over three months, it changed -51.42%. In one year it has changed -82.84% and within that year its 52 week high was 4.34 and its 52 week low was 0.42. VIVE stock is 9.88% above its 52 week low.
Our calculations result in a 200 day moving average of 1.61 and a 50 day moving average of 0.55. Right now, VIVE stock is trading -71.35% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $21.5m with 46.5m shares outstanding and a float of 43.3m shares. Trading volume was 503,391 shares and has experienced an average volume of 609,507 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Viveve Medical was -1.63 which ended on 31st of December 2018. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.32.
Below was the last reported quarterly diluted earnings per share:
|1st||Qtr 2019||Reported 05-09-2019:||-0.22|
|4th||Qtr 2018||Reported 03-14-2019:||-0.38|
|3rd||Qtr 2018||Reported 11-08-2018:||-0.39|
|2nd||Qtr 2018||Reported 08-09-2018:||-0.37|
|1st||Qtr 2018||Reported 05-10-2018:||-0.49|
The growth of the EPS is critical in understanding the current valuation of Viveve Medical; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -32.80% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 10.20% of insider ownership and 66.80% of institutional ownership.
The beta was calculated to be 0.05.
Based on last reported financials, the company’s return on assets is -103.76%, price-to-sales is 1.20 and price-to-book is 4.09.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
1 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
0 : Overall Result